PROMISE: Percutaneous peRipheral cannulatiOn for Minimally-InvaSive Heart Valve surgEry

Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Jul 17, 2023

Keywords

ClinConnect Summary

The PROMISE trial is studying a new approach to heart valve surgery that aims to make the procedure safer and less invasive. Traditionally, doctors perform heart valve surgery through a large cut in the chest, which can lead to longer recovery times. This trial is focusing on a less invasive method that uses smaller openings and special devices to access the heart through blood vessels. The goal is to see if these new techniques can reduce complications and improve recovery for patients with heart valve diseases, such as issues with the mitral, aortic, or tricuspid valves.

To participate in this trial, patients should be between 65 and 74 years old and have had minimally-invasive heart valve surgery at one of six specialized centers in Germany. There are no specific exclusion criteria, so many patients may be eligible. Those who join the trial can expect to be monitored for any complications during and after their surgery, and their experiences will help researchers determine if these new techniques are as effective as the traditional methods. This study is currently recruiting participants, and your involvement could help advance heart surgery techniques for the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Retrospective analysis of all patients undergoing minimally-invasive heart valve surgery using novel endovascular closure devices for percutaneous cannulation within 6 high-volume heart valve centres in Germany.
• Exclusion Criteria:
• • none